Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Xijing Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06876636CT.gov Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02721433CT.gov 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases | — | Completed | — | — | — |
NCT01654367CT.gov Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer | — | Unknown | — | — | — |
NCT01067989CT.gov Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00873808CT.gov S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307 | — | Withdrawn | — | — | — |
NCT00558272CT.gov Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease | — | Completed | — | — | — |
NCT00566618CT.gov Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis | — | Completed | — | — | — |
NCT00525759CT.gov Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer | — | Completed | — | — | — |
NCT00556374CT.gov Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | — | Completed | — | — | — |
NCT00365105CT.gov Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT00301886CT.gov S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone | — | Withdrawn | — | — | — |
NCT00326820CT.gov Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer | — | Unknown | — | — | — |
NCT00127205CT.gov S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. | — | Completed | — | — | — |
NCT00412022CT.gov HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. | — | Unknown | — | — | — |
NCT00060138CT.gov Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases | — | Completed | — | — | — |
NCT00172068CT.gov Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zoledronate (this asset) | Xijing Hospital | Approved | BB · 69 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Vitamin D | University of Illinois at Chicago | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Adriamycin | George Washington University | P4 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Peg-Rhg-Csf | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Zoledronate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Carcinoma In The Bone | — | P4 | BBB · 76 |
| Osteoporosis | — | P4 | BBB · 73 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Zoledronate in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/zoledronate-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →